Exosome-based Therapeutic Delivery
Oncology
Pre-clinicalActive
Key Facts
About EriVan Bio
EriVan Bio is a private, pre-revenue biotech company developing exosome-based research tools and therapeutic candidates. The company offers a portfolio of exosomes derived from adipose stem cells, bovine milk, and human plasma for research and biopharmaceutical manufacturing. With a leadership team combining scientific and entrepreneurial expertise, EriVan aims to advance exosome technology for targeted drug delivery, particularly in oncology, and diagnostics. Its foundation stems from award-winning academic research on miRNAs and extracellular vesicles.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |